Ruzanna Papyan: Week 1 of Global Access To AntiGD2 Campaign

Ruzanna Papyan, Pediatric Oncologist at Pediatric Cancer and Blood Disorders Center of Armenia, shared the following on LinkedIn:

“Week 1 of Global Access To AntiGD2 Campaign

Today marks the beginning of our campaign to advocate for the inclusion of anti-GD2 therapies in the WHO Essential Medicines List! Join us in raising awareness about the critical role of anti-GD2 treatments in fighting high-risk neuroblastoma.

Our journey starts with a deep dive into the groundbreaking article published in “Cancers” by Larrosa C, Mora J, Cheung NK. This paper delves into the global landscape of monoclonal antibodies (mAbs) in pediatric cancer treatment, with a special focus on anti-GD2 mAbs for neuroblastoma.

“Global Impact of Monoclonal Antibodies (mAbs) in Children: A Focus on Anti-GD2” offers invaluable insights into the complexities of transitioning mAbs from basic research to clinical use, particularly in the context of childhood malignancies. It also highlights the limited availability of mAbs for pediatric solid tumors and underscores the inequities in global drug access.

Together, we can make a difference by advocating for the inclusion of anti-GD2 therapies in the World Health Organization Essential Medicines List.

Join us in our mission to ensure global access to AntiGD2 and make sure every child with high-risk neuroblastoma has access to the treatments they need to overcome this disease.

Stay tuned for more updates and ways to get involved! Together, we can make a difference.”

Source: Ruzanna Papyan/LinkedIn
OncoDaily